Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
February 24 2022 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Lawrence Lee, MD,
MBBS, FRANZCO, FRACS, Associate Professor of Ophthalmology at the
University of Queensland and Director of the City Eye Center in
Brisbane, Australia, will present pivotal safety and efficacy data
from Outlook Therapeutics’ Phase 3 NORSE TWO registration trial
evaluating ONS-5010, an investigational ophthalmic formulation of
bevacizumab, for use in wet AMD. The presentation will take place
virtually at the RANZCO 52nd Annual Scientific Congress on
Saturday, February 26, 2022 from 9:45 PM – 10:15 PM ET (Sunday,
February 27, 2022 from 13:45 PM – 14:15 PM AEDT).
“The clinical results from the pivotal NORSE TWO
trial are exciting,” said Dr. Lee. “As a practicing
ophthalmologist, I would welcome the addition of an on-label
bevacizumab that is specifically formulated to meet the exacting
standards in ophthalmology. If approved by the FDA, ONS-5010 will
allow clinicians to treat their retina patients with a product that
avoids the risks of off-label, repackaged IV bevacizumab.”
Details for the presentation are as follows:
Safety and efficacy results of ONS-5010,
an ophthalmic bevacizumab from the NORSE TWO phase 3 study of
monthly intravitreal ONS-5010 in subjects with wet AMD
Presenter: Lawrence Lee, MD, MBBS, FRANZCO,
FRACSRapid Fire Session: RetinaDate and time: Saturday, February
26, 2022 from 9:45 PM – 10:15 PM ET (Sunday, February 27, 2022 from
13:45 PM – 14:15 PM AEDT)
For more information and to register for this
event, please visit RANZCO 2022.
About RANZCO
The Royal Australian and New Zealand College of
Ophthalmologists (RANZCO) is the medical college responsible for
the training, examination and professional development of
ophthalmologists in Australia and New Zealand. We seek to improve
eye health across Australia and New Zealand, as well as further
afield, by providing best quality education, training and
continuing professional development; by promoting eye health care
and the work of ophthalmologists; and through collaboration with
others involved in the delivery of eye health care. For more
information, please visit RANZCO.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024